R&D setbacks are not palatable at premium valuations
08/09/26 -"The last one week’s string of R&D failures may raise concerns around Novartis’s prospects beyond 2030, though they may not impact the mid-term outlook. While a healthy longer-term ..."
Pages
69
Language
English
Published on
08/09/26
You may also be interested by these reports :
08/09/26
The last one week’s string of R&D failures may raise concerns around Novartis’s prospects beyond 2030, though they may not impact the mid-term ...
04/09/26
While we have tweaked our earnings estimates slightly higher, the decline in our target price is owing to the removal of a peer which was skewing the ...
04/09/26
We have tweaked our earnings estimates lower and considering the recent late-stage setbacks for cardiovascular (Wainua) and oncology (Volrustomig) ...
27/08/26
While immense pricing and competitive pressures from Eli Lilly and compounding pharmacies have proven to be a nightmare for Novo Nordisk in the last ...